Phenotypic Disease Modeling for Metabolic and Cardiovascular Diseases

By

Phenotypic Disease Modeling for Metabolic and Cardiovascular Diseases

Watch our on-demand webinar and join our speaker Flavio Bonanini, Scientist at MIMETAS, for an in-depth look into advanced disease modeling and drug screening for metabolic and cardiovascular diseases. This webinar will explore cutting-edge approaches to modeling the disease progression of MASH and evaluating the efficacy and toxicity of novel treatments in the context of related disease comorbidities such as obesity and weight loss.

Phenotypic Disease Modeling for Metabolic and Cardiovascular Diseases

Watch our on-demand webinar and join our speaker Flavio Bonanini, Scientist at MIMETAS, for an in-depth look into advanced disease modeling and drug screening for metabolic and cardiovascular diseases. This webinar will explore cutting-edge approaches to modeling the disease progression of MASH and evaluating the efficacy and toxicity of novel treatments in the context of related disease comorbidities such as obesity and weight loss.

Phenotypic Disease Modeling for Metabolic and Cardiovascular Diseases

Watch our on-demand webinar and join our speaker Flavio Bonanini, Scientist at MIMETAS, for an in-depth look into advanced disease modeling and drug screening for metabolic and cardiovascular diseases. This webinar will explore cutting-edge approaches to modeling the disease progression of MASH and evaluating the efficacy and toxicity of novel treatments in the context of related disease comorbidities such as obesity and weight loss.

Phenotypic Disease Modeling for Metabolic and Cardiovascular Diseases

Watch our on-demand webinar and join our speaker Flavio Bonanini, Scientist at MIMETAS, for an in-depth look into advanced disease modeling and drug screening for metabolic and cardiovascular diseases. This webinar will explore cutting-edge approaches to modeling the disease progression of MASH and evaluating the efficacy and toxicity of novel treatments in the context of related disease comorbidities such as obesity and weight loss.

Phenotypic Disease Modeling for Metabolic and Cardiovascular Diseases

Watch our on-demand webinar and join our speaker Flavio Bonanini, Scientist at MIMETAS, for an in-depth look into advanced disease modeling and drug screening for metabolic and cardiovascular diseases. This webinar will explore cutting-edge approaches to modeling the disease progression of MASH and evaluating the efficacy and toxicity of novel treatments in the context of related disease comorbidities such as obesity and weight loss.

Phenotypic Disease Modeling for Metabolic and Cardiovascular Diseases

Watch our on-demand webinar and join our speaker Flavio Bonanini, Scientist at MIMETAS, for an in-depth look into advanced disease modeling and drug screening for metabolic and cardiovascular diseases. This webinar will explore cutting-edge approaches to modeling the disease progression of MASH and evaluating the efficacy and toxicity of novel treatments in the context of related disease comorbidities such as obesity and weight loss.

By

Phenotypic Disease Modeling for Metabolic and Cardiovascular Diseases

Watch our on-demand webinar and join our speaker Flavio Bonanini, Scientist at MIMETAS, for an in-depth look into advanced disease modeling and drug screening for metabolic and cardiovascular diseases. This webinar will explore cutting-edge approaches to modeling the disease progression of MASH and evaluating the efficacy and toxicity of novel treatments in the context of related disease comorbidities such as obesity and weight loss.

Phenotypic Disease Modeling for Metabolic and Cardiovascular Diseases

Watch our on-demand webinar and join our speaker Flavio Bonanini, Scientist at MIMETAS, for an in-depth look into advanced disease modeling and drug screening for metabolic and cardiovascular diseases. This webinar will explore cutting-edge approaches to modeling the disease progression of MASH and evaluating the efficacy and toxicity of novel treatments in the context of related disease comorbidities such as obesity and weight loss.

By